Ocumension Therapeutics (1477) AI Stock Analysis

• Market Cap: HK$7.51B
• Dividend Yield: N/A
• Average Volume (3M): 10.21M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: 66.72%
• EPS Growth: 33.68%
• Country: HK
• Employees: 489
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 834,780,500
• 10 Day Avg. Volume: 9,449,683
• 30 Day Avg. Volume: 10,212,221
• PEG Ratio: -1.31
• Price to Book (P/B): 1.91
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -61.94
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$6.93
• Price Target Upside: -24.26% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 55 Neutral
• Price Target: HK$9.50 ▲(3.83%Upside)

Ocumension Therapeutics' score is primarily driven by strong revenue growth and a solid balance sheet, but is weighed down by profitability challenges and cash flow constraints. Technical indicators show positive momentum, yet valuation concerns persist due to negative earnings.

Ocumension Therapeutics Business Overview & Revenue Model

Company Description

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. The company discovers, develops, and commercializes therapies for ophthalmic patients. It offers drugs for the treatment of blepharitis, infective and allergic conjunctivitis, dry eye, cataract, glaucoma and ocular hypertension, postoperative inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, cornea graft rejection, myopia, and optic neuritis. As of December 31, 2021, the company had 20 drug assets in its portfolio. Ocumension Therapeutics was founded in 2017 and is headquartered in Suzhou, the People's Republic of China.

How the Company Makes Money

Ocumension Therapeutics generates revenue primarily through the sale of its ophthalmic products and therapies. The company's revenue model is centered around the commercialization of its proprietary and licensed products, which are marketed within China and internationally. Key revenue streams include direct sales to healthcare providers, distribution partnerships, and collaborations with other pharmaceutical companies for co-development and co-marketing opportunities. Additionally, Ocumension may engage in licensing agreements, allowing other companies to market its products in different regions, which can provide significant royalty income. The company's earnings are also influenced by its research and development activities, which may lead to new product launches, further enhancing its revenue potential.

Ocumension Therapeutics Financial Statement Overview

Summary

Ocumension Therapeutics exhibits strong revenue growth with a 69.4% increase, but its profitability is hindered by negative EBIT and net income. While the balance sheet is strong with low leverage and high equity, cash flow concerns are notable with zero operating and free cash flow.

Income Statement

Ocumension Therapeutics showcases strong revenue growth, with a notable increase in total revenue from the previous year (+69.4%). However, the company continues to operate at a loss with negative EBIT and net income, impacting its net profit margin (-64.3%) and EBIT margin (-73.4%). Gross profit margin remains healthy at 53.9%, indicating operational efficiency in production.

Balance Sheet

The company's balance sheet is strong with high equity levels, as evidenced by a low debt-to-equity ratio (0.01) and a high equity ratio (94.96%). However, the return on equity is negative (-7.11%) due to sustained net losses. The low leverage and high cash reserves suggest financial stability, but profitability remains a concern.

Cash Flow

The cash flow position is challenging, with zero operating cash flow and free cash flow, indicating potential liquidity issues. The absence of cash flow from operations despite revenue growth highlights operational cash constraints. Previous periods show negative free cash flow, suggesting ongoing cash management challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	417.31M	246.37M	158.96M	56.15M	13.10M
Gross Profit	225.06M	144.37M	102.92M	36.94M	11.37M
EBITDA	-260.05M	-320.62M	-359.98M	-371.30M	-2.26B
Net Income	-268.27M	-379.79M	-402.64M	-134.78M	-2.26B
Balance Sheet
Total Assets	3.97B	3.27B	3.04B	3.33B	2.60B
Cash, Cash Equivalents and Short-Term Investments	769.21M	1.05B	1.29B	1.77B	2.03B
Total Debt	25.78M	137.98M	29.58M	11.21M	7.24M
Total Liabilities	200.19M	351.03M	295.04M	222.88M	97.23M
Stockholders Equity	3.77B	2.92B	2.75B	3.11B	2.50B
Cash Flow
Free Cash Flow	-408.97M	-539.79M	-510.66M	-861.66M	-517.18M
Operating Cash Flow	-178.83M	-177.93M	-200.66M	-196.85M	-212.57M
Investing Cash Flow	275.91M	-259.78M	229.15M	-1.35B	629.70M
Financing Cash Flow	-213.79M	108.66M	-9.22M	668.85M	1.53B

Ocumension Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.15
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Neutral. The current price of 9.15 is below the 20-day moving average (MA) of 10.04, above the 50-day MA of 7.81, and above the 200-day MA of 5.65, indicating a neutral trend. The MACD of 0.47 indicates Positive momentum. The RSI at 48.77 is Neutral, neither overbought nor oversold. The STOCH value of 11.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1477.

Ocumension Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0775	65 Neutral	HK$8.07B	―	-3.29%	―	3.76%	-833.33%
1477	55 Neutral	HK$7.51B	―	-8.04%	―	66.72%	33.68%
2616	55 Neutral	HK$6.94B	―	-22.23%	―	-14.17%	76.00%
Sector *	52 Neutral	$7.45B	0.27	-61.87%	2.30%	16.62%	1.04%
2157	51 Neutral	HK$8.90B	―	-51.40%	―	58.75%	-1310.16%
6622	48 Neutral	HK$1.34B	―	-12.04%	―	260.78%	40.04%
6955		HK$7.04B	82.07	4.95%	―	―	―

Ocumension Therapeutics Corporate Events

Ocumension Therapeutics Updates Nomination Committee

Ocumension Therapeutics has announced changes to its Nomination Committee in response to upcoming amendments to the Corporate Governance Code. Dr. Qin XIE and Mr. Ting Yuk Anthony WU have been appointed as new members, effective June 30, 2025, enhancing the committee’s composition with a blend of independent and non-executive directors.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Announces Board Composition and Roles

Ocumension Therapeutics has announced the composition of its board of directors and the roles of each member, highlighting the leadership structure and committee memberships. This announcement provides clarity on the governance of the company, which is crucial for stakeholders to understand the decision-making framework and oversight within the organization.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Updates Nomination Committee Terms

Ocumension Therapeutics has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. This move is part of the company’s efforts to ensure compliance with applicable laws and listing standards, and to enhance the governance process by including a diverse and independent board composition.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Revamps Share Option Scheme to Boost Employee Incentives

Ocumension Therapeutics announced the cancellation and re-granting of options as part of its 2021 Share Option Scheme. The company canceled 4,018,842 options and re-granted 2,813,189 replacement options to 155 existing grantees, representing approximately 0.35% of the total shares. Additionally, Ocumension granted 15,462,865 new options and 8,952,185 awards to 430 grantees as further incentives, representing 1.90% and 1.10% of the total shares, respectively. This move aims to provide meaningful incentives and retain key personnel by aligning the exercise price with the prevailing market price of shares.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Successfully Passes All AGM Resolutions

Ocumension Therapeutics announced that all resolutions proposed at their Annual General Meeting on June 19, 2025, were passed as ordinary resolutions. Key resolutions included the re-election of directors, the re-appointment of auditors, and the authorization for the board to manage shares, reflecting strong shareholder support and potentially enhancing the company’s governance and operational capabilities.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Gains Approval for Phase III Trial of Presbyopia Treatment in China

Ocumension Therapeutics has received authorization to initiate a phase III clinical trial for OT-802, a self-developed treatment for presbyopia, in China. This development underscores the company’s research capabilities and highlights the significant commercial potential in the underserved presbyopia treatment market in the region.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension’s OT-703 Approved for Study in Hainan

Ocumension Therapeutics announced that its product OT-703, an injectable fluocinolone intravitreal implant for diabetic macular edema, has been approved for a real-world study in Hainan, China. This approval marks a significant step in the company’s efforts to expand its presence in the Asian market, following its exclusive licensing agreement with Alimera Sciences for the development and commercialization of ILUVIEN in Greater China and other regions.

The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.

Ocumension Therapeutics Announces 2025 Annual General Meeting

Ocumension Therapeutics has announced its upcoming annual general meeting scheduled for June 19, 2025, in Shanghai. The meeting will address several key resolutions, including the adoption of the company’s financial statements for 2024, the re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors. Additionally, the meeting will consider authorizing the board to issue additional shares, which could impact the company’s capital structure and market operations.